Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cholesterol embolisation after thrombolytic therapy

J C Blankenship1

  • 1Geisinger Medical Center, Danville, Pennsylvania, USA.

Drug Safety
|February 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Importance of delayed imaging for blunt renal trauma.

World journal of surgery·2002
Same author

Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT--(Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II Trial.

The American journal of cardiology·2001
Same author

Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial.

Journal of the American College of Cardiology·2001
Same author

Effectiveness of transluminal extraction atherectomy for debulking saphenous vein graft in-stent restenosis.

The American journal of cardiology·2001
Same author

Platelets and coronary intervention: some practical precautions.

The Journal of invasive cardiology·2000
Same author

Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials.

The American journal of medicine·2000
Same journal

Implementation Aspects of a Medicines Shortage Policy Tool: Evidence from Australia's Serious Scarcity Substitution Instruments.

Drug safety·2026
Same journal

Availability and Communication of Risk Management Strategies for Pregnancy Category X Medicines across Australian Medicine Information Sources.

Drug safety·2026
Same journal

The Bidirectionality of Lawyer Reporting Bias in Disproportionality Analysis.

Drug safety·2026
Same journal

Safety of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Longitudinal Analysis.

Drug safety·2026
Same journal

Developing a Hierarchical Algorithm to Identify Pregnancies and Determine Gestational Age from Nationwide Linked Health Data in Taiwan.

Drug safety·2026
Same journal

Safety and Effectiveness of Direct Oral Anticoagulants Versus Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis: A Systematic Review and Meta-analysis.

Drug safety·2026
See all related articles

Cholesterol embolisation is a potential complication of thrombolytic therapy for acute myocardial infarction (MI). While difficult to diagnose, its risks are outweighed by the benefits of MI treatment.

Area of Science:

  • Cardiology
  • Vascular Medicine

Background:

  • Thrombolytic therapy is a cornerstone treatment for acute myocardial infarction (MI).
  • Cholesterol embolisation syndrome (CES) is a rare but serious complication associated with procedures involving aortic manipulation.

Purpose of the Study:

  • To investigate the incidence and clinical significance of cholesterol embolisation in patients undergoing thrombolytic therapy for acute MI.
  • To assess the diagnostic challenges and clinical outcomes associated with CES in this patient population.

Main Methods:

  • Retrospective review of patients receiving thrombolytic therapy for acute MI.
  • Analysis of clinical data, diagnostic findings, and patient outcomes.

Main Results:

  • Cholesterol embolisation was reported in 27 patients receiving thrombolytic therapy for acute MI.

Related Experiment Videos

  • The study suggests that diagnosed cases may represent only a fraction of the actual incidence, indicating underdiagnosis.
  • Clinical manifestations of CES can lead to significant morbidity and mortality.

    • Conclusions:

    • Cholesterol embolisation is an under-recognized complication of thrombolytic therapy for acute MI.
    • Despite diagnostic difficulties, heightened clinical suspicion is crucial for timely recognition and management.
    • The survival benefits of thrombolytic therapy for acute MI outweigh the risks of CES, but vigilance is warranted.